Jul 08, 2025 09:31 JST

Source: Eisai

Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

TOKYO, July 8, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has been selected for the highest rating of “Supplier Engagement Leader” in the Supplier Engagement Rating by the global environmental non-profit organization CDP.(1)

The Supplier Engagement Assessment evaluates how effectively companies are working with suppliers to address climate change issues. In its responses to the CDP Climate Change Questionnaire on 'Governance', 'Targets', 'Scope 3 emissions(2)' and 'Value chain engagement', Eisai’s efforts to engage with suppliers were highly regarded, leading to this selection. To conduct environmentally conscious business activities throughout our entire supply chain, Eisai asks business partners to comply with the “Eisai Global Code of Conduct for Business Partners(3)” which clearly states Eisai’s requirement for environmental conservation. Collaboration with suppliers is also strengthened by conducting sustainability assessments of partners and providing feedback on the results.

Eisai identifies “Business activities with consideration for the global environment” as one of its material issues. Based on the “Eisai Network Companies Environmental Protection Policy”, Eisai is promoting responses to climate change as key environmental activities across the group. Eisai is working towards the realization of a decarbonized society, including receiving approval for the SBT 1.5°C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI)Race to Zero Circle, which calls for achieving net zero by 2050.(4)

Please refer to Eisai’s website for more detailed information about its environmental activities.

The preservation of the global environment is essential for realizing Eisai’s corporate concept of human health care (hhc). Eisai will contribute to empowering people to “realize their fullest lives” through our climate change initiatives.

(1)A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system.
(2)Indirect greenhouse gas emissions across the entire corporate value chain
(3)Please refer here for further details
(4)Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GASREDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050
https:/www.eisai.com/news/2024/news202412.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

 

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
 
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
 
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
More Press release >>

Latest Press Release


More Latest Release >>